Avalon to collaborate with ChemDiv to develop oncology drugs

By E. Janene Geiss

Philadelphia, July 26 - Avalon Pharmaceuticals, Inc. and ChemDiv, Inc. said Wednesday that they will collaborate to discover and develop small molecule oncology therapeutics.

Avalon said it will use its proprietary AvalonRx platform to discover new active compounds in screens against selected targets and target pathways, according to a company news release.

ChemDiv said it will provide Avalon access to its discovery outsource services platform, including the world's largest commercially available chemical library, as well as medicinal and synthetic chemistry for the discovery and development of new active compounds.

Avalon and ChemDiv said they will share in the costs of development and the value of any lead candidate resulting from their joint research efforts.

Additional terms of the agreement provide Avalon with the right to select 200,000 compounds from the ChemDiv library for use in all of Avalon's discovery programs, officials said.

ChemDiv is a privately held contract research organization based in San Diego.

Avalon is a Germantown, Md., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.